NON-SMALL CELL LUNG CANCER

This early-stage trial is testing a new vaccine called YMN-136 in 9 people with advanced non-small cell lung cancer that has not responded to standard treatments. The vaccine uses self-amplifying RNA to train the immune system to attack cancer cells that produce a protein called …

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This phase II trial is testing whether removing the usual safety margin around the tumor during online adaptive stereotactic body radiotherapy (SBRT) can lower breathing-related side effects while still controlling early-stage non-small cell lung cancer or limited lung metastases…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This early-stage trial is testing a new daily pill called DZD6008 in 140 people with advanced non-small cell lung cancer that has specific EGFR mutations. The study aims to see if the drug is safe and can shrink tumors. It is currently recruiting participants.

This early-phase trial is testing a new drug called OKN4395, which blocks certain inflammatory signals, both alone and combined with the immunotherapy pembrolizumab. The study will enroll about 146 people with advanced solid tumors (including lung, colorectal, and stomach cancers…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This Phase 3 trial is testing whether a combination of two drugs, datopotamab deruxtecan (Dato-DXd) and rilvegostomig, works better than the current standard treatment pembrolizumab for people with advanced non-squamous lung cancer that has high PD-L1 levels. About 675 participan…

This expanded access program offers zidesamtinib (NVL-520), an oral tablet, to adults with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have no satisfactory treatment options and cannot join a clinical trial. Participants must have tried at least on…

This phase 3 trial compares two immune-boosting drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific marker (PD-L1). About 880 participants will rece…

This phase 2 trial tests fingolimod, a drug already used for multiple sclerosis, in 38 adults with advanced non-small cell or small cell lung cancer that worsened after chemo-immunotherapy. Participants take a 0.5 mg pill daily. The study first checks safety, then looks at whethe…

This study tests whether applying a surgical sealant (Progel Platinum) to staple lines during lung cancer surgery can reduce the time patients need a chest tube. About 160 adults having minimally invasive lung lobectomy for non-small cell lung cancer will be randomly assigned to …

This early-phase trial tests whether adding carotuximab to the standard drug osimertinib is safe for people with advanced EGFR-mutated non-small cell lung cancer. About 60 participants whose cancer has progressed on prior treatments will receive both drugs. The main goal is to fi…

This study tests a new drug called CKD-703 in people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has a specific marker (c-Met). The drug is designed to seek out and destroy cancer cells while sparing healthy ones. The trial has three part…

This phase 3 trial tests whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer whose disease has progressed after prior immunotherapy. About 536 adults will receive either ivonescimab or a place…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This large Phase 3 trial is testing whether a new immunotherapy drug called ivonescimab, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. The st…

This phase 2 trial tests zanidatamab, a drug that targets cancer cells with a HER2 gene alteration, in 105 adults with advanced lung, endometrial, colorectal, head & neck, or sarcoma cancers. Participants receive the drug every 3 weeks, and doctors monitor tumor shrinkage and sid…

This early-stage trial is testing whether two oral drugs, GEN-725 and Dositinib, can safely shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer. About 110 participants will receive the combination daily until their disease worsens or side effects become t…

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This phase 2 trial tests a new drug called nelmastobart combined with the chemotherapy docetaxel in 62 people with advanced non-small cell lung cancer that no longer responds to platinum chemo or immunotherapy. The goal is to see if the combination can slow cancer growth and impr…

This Phase 3 trial tests whether adding Sigvotatug Vedotin to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 participants will receive either the combinati…

This phase 2 trial is testing a combination of three drugs—datopotamab deruxtecan, carboplatin, and pembrolizumab—in 46 people with non-small cell lung cancer that has spread to the brain and who have not had prior treatment for those brain tumors. The goal is to see how well the…

This study tests a new combination of two oral drugs, DZD6008 and sunvozertinib, in 160 adults with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to check safety, how the drugs move through the body, and whether they shrink tumors. It is the fir…

This early-stage trial is testing a new approach for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). Doctors take immune cells from the patient's own tumor, boost them in the lab with a molecule called CD40L, and then giv…

This phase 2 trial tests whether adding BIO 300 (a synthetic soy compound) to standard radiation therapy can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease. About 25 participants will re…

This study tests a new drug called andamertinib, alone or with chemotherapy, against standard chemotherapy in people with advanced non-squamous lung cancer that has unusual EGFR mutations. About 40 participants who have not had prior treatment will be enrolled. The goal is to see…

This study tests a new drug called izalontamab brengitecan against standard chemotherapy in 500 people with a specific type of lung cancer (EGFR-mutated non-small cell) that has stopped responding to current targeted pills. The goal is to see if the new drug can delay cancer grow…

This phase 3 study is testing whether a new drug called telisotuzumab vedotin works better than the standard chemotherapy docetaxel for adults with a certain type of advanced non-small cell lung cancer. The cancer must have high levels of a protein called c-Met. About 698 partici…

This study tests whether a dye called indocyanine green (ICG) can help surgeons see the exact boundary of a lung cancer tumor during robotic surgery. The dye makes the healthy lung glow, leaving the cancerous segment dark. The surgeon then removes only that dark segment, sparing …

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This phase 3 trial tests two oral drugs (IN10018 and D-1553) against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 400 participants who have not had prior treatment will be randomly assig…

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

This study tests a new drug called ivonescimab, given with standard chemotherapy and focused radiation (SRS), for people with non-small cell lung cancer that has spread to the brain. The goal is to find the safest dose and see if it helps control the brain tumors. About 53 adults…

This phase 2 study is testing stereotactic body radiation therapy (SBRT) for people with non-small cell lung cancer or other cancers that have spread to the lung. Instead of daily radiation for weeks, participants receive high doses in just 3 to 10 sessions over 1 to 2 weeks. The…

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…

This phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent lung cancer from returning after surgery in patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 levels of 1% or higher. About 390 participants will either receive cem…

This phase 2 trial is testing the immunotherapy drug pembrolizumab, given alone or with chemotherapy, in 318 Black patients with advanced non-small cell lung cancer. The goal is to see how well these treatments work in real-world settings and to find biological markers that predi…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This study is testing whether a fecal transplant from a healthy donor, combined with the immunotherapy drug pembrolizumab, can help people with a certain type of advanced lung cancer (PD-L1 positive non-small cell lung cancer) that has not responded to previous treatments. The tr…

This early-phase trial is testing an experimental drug called BL-M24D1 in 33 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tu…

This study tests two experimental drugs, SI-B001 and SI-B003, given together with or without chemotherapy in 160 people with advanced non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the combination shrinks tumors. Participants must …

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

This phase 3 trial compares two immunotherapy combinations for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of 1% or higher. One group receives nivolumab plus relatlimab with chemotherapy, while the other gets pembrolizumab with chemotherapy. The s…

This early study tests a drug called TolueneSulfonamide, injected directly into the chest cavity, to see if it can safely reduce fluid buildup in people with lung cancer. About 105 participants will receive the drug three times a week for one week. The goal is to control the flui…

This early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Particip…

This early-phase trial is testing an experimental oral drug called OCT-598 in 51 adults with advanced solid tumors, including breast, lung, and prostate cancers. The study aims to find the safest dose and see if the drug works alone or with standard chemotherapy. It is too early …

This phase 2 trial is testing whether combining three anti-cancer drugs—carboplatin, paclitaxel, and ramucirumab—can shrink tumors or slow their growth in people with advanced non-squamous non-small cell lung cancer. The study enrolls adults whose cancer has progressed after at l…

This study tests whether adding an experimental drug (ES102) to an approved immunotherapy (toripalimab) can shrink tumors in people with advanced non-small cell lung cancer that has not responded to prior treatment. About 40 adults aged 18-75 will receive the combination and be m…

This study tests whether adding two experimental drugs (livmoniplimab and budigalimab) to standard chemotherapy can help people with untreated metastatic non-squamous non-small cell lung cancer live longer or shrink their tumors better than the current standard treatment (pembrol…

This study tests a new experimental drug, PF-08634404, combined with other cancer medicines in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. About 162 adults w…

This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…

This study tests a new medicine, PF-08634404, given alone or with chemotherapy for adults with early or locally advanced non-small cell lung cancer. The goal is to see if it can shrink tumors before surgery or prevent cancer from returning after other treatments. About 120 partic…

This study looks at whether adding a precise radiation dose to liver tumors can make standard immunotherapy work better for people with stage IV non-small cell lung cancer. About 68 adults whose cancer has spread to the liver will either get standard drug therapy alone or standar…

This study tests whether anlotinib hydrochloride capsules can help prevent lung cancer from coming back in patients who still had cancer cells after surgery and chemotherapy. About 64 adults with stage IIA-IIIA non-small cell lung cancer will take the drug daily. The main goal is…

This study tests a new drug called BLU-924 in people with advanced pancreatic, lung, or colorectal cancer that has a specific KRAS gene change. The drug aims to block the cancer's growth signals. The trial will check safety, the right dose, and whether the drug shrinks tumors, al…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This early-stage study tests a new treatment using a patient's own immune cells, engineered to recognize and attack cancer cells with a specific KRAS mutation (G12D). It is for adults with advanced solid tumors like lung, colorectal, pancreatic, or endometrial cancer that have no…

This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses specially engineered natural killer (NK) immune cells that target two cancer-related proteins on tumor cells. Participants receive…

This phase 3 trial tests whether adding metformin (a common diabetes medicine) to standard targeted therapy (tyrosine kinase inhibitors) can help people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). About 312 participants will receive e…

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This study tests an experimental drug called HMBD-501 in 180 adults with advanced solid tumors (melanoma, lung, or breast cancer) that have a protein called HER3 on their cells and have stopped responding to standard treatments. The trial has two phases: first, finding the safest…

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This study tests whether a new combination of special radiation (SFRT), an immunotherapy drug (tislelizumab), and standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to make the cancer small enough to operate on. …

This early-stage study tests a new oral drug (PF-07799544) alone or with another drug for adults with advanced solid tumors that have a BRAF V600 mutation, including melanoma, lung, thyroid, and brain cancers. The goal is to check safety and how well the drugs work. About 124 par…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study tests whether adding a nitroglycerin patch (a heart medication) to standard radiation therapy can better shrink brain tumors in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. About 74 adults will be ran…

This study tests a new drug called volrustomig combined with other cancer treatments for people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults will take part in this early-stage trial.

This study is for people with a specific type of lung cancer (EGFR-mutant) that has spread to other parts of the body after they finished a previous treatment (osimertinib). The goal is to see if combining osimertinib with chemotherapy can help control the cancer for longer. Abou…

This early study tests a new type of radiation surgery called hypervision proton surgery for people with early-stage non-small cell lung cancer. The goal is to see if a single, high-dose treatment is safe and can control the tumor. Only 12 participants will be enrolled, and resea…

This early-phase study tests a new drug called EPI-326 in people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. About 110 participants will take part.

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This Phase 3 study compares a new drug, neladalkib (NVL-655), to the current standard alectinib for people with ALK-positive advanced non-small cell lung cancer who have not had prior treatment. About 450 participants will be randomly assigned to receive either NVL-655 or alectin…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This phase 2 trial tests TQB2102, a drug that delivers a powerful toxin directly to cancer cells with a specific genetic change (HER2 abnormality). The study aims to see if the drug can shrink tumors in 270 adults with advanced non-small cell lung cancer that cannot be removed by…

This study compares two treatments for early-stage lung cancer in patients who are high-risk for surgery: removing part of the lung (sublobar resection) versus precise, high-dose radiation (stereotactic ablative radiotherapy). About 272 participants will be randomly assigned to o…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-stage study is testing a new drug called DO-2 in people with advanced solid tumors (like lung cancer) that have a specific genetic change (MET mutation) and have run out of standard treatments. The main goal is to check the drug's safety and how the body processes it. …

This study tests a targeted cancer pill called lazertinib, given alone or with chemotherapy, before surgery for a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). About 160 adults with early to mid-stage disease will receive the treatment for three cycles be…

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

This early-stage trial is testing a new cancer vaccine called BNT116, alone or with other drugs, in people with advanced non-small cell lung cancer. The main goal is to find a safe dose and check for side effects. About 320 participants will be enrolled across several groups, inc…

This early-phase trial is testing a new treatment called VET3-TGI, a virus engineered to attack cancer cells. It is given alone or with the immunotherapy drug atezolizumab to up to 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals…

This study tests an experimental drug called CP-383 in 150 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if CP-383 can slow or stop cancer growth and to find the safest and most effective dose. Participants take the drug dail…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with a specific type of advanced lung cancer (MET-positive non-squamous non-small cell lung cancer) live longer without their cancer growing. About 300 adults who have not had prio…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This phase 2 trial is testing a new drug called SHR-1826 in 90 people with advanced non-small cell lung cancer that has worsened after other treatments. Participants receive the drug by IV every three weeks. The study aims to see if the drug can shrink tumors and how safe it is.

This phase 3 trial is testing whether adding an extra immunotherapy drug (tremelimumab) and more chemotherapy to the standard treatment (durvalumab) can lower the amount of cancer DNA found in the blood of people with stage III non-small cell lung cancer. The study enrolls 48 par…

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment will participate. The g…

This phase 3 trial tests whether adding the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) to the standard pill osimertinib can better control advanced EGFR-mutated non-small cell lung cancer compared to osimertinib alone. About 582 adults with stage IIIB/IV or recurre…

This study compares two types of anesthesia—propofol-based intravenous anesthesia versus inhaled gas anesthesia—in over 5,300 people having surgery for early-stage non-small cell lung cancer. The goal is to see if one method leads to a longer time before the cancer comes back. Pa…

This study tests a new drug called pumitamig (BNT327) combined with standard chemotherapy (docetaxel) in 60 people with advanced non-small cell lung cancer that got worse after initial treatment. The goal is to see if the combination is safe and shrinks tumors. It is an early-pha…

This study tests a new drug, telisotuzumab adizutecan, in people with advanced EGFR-mutated non-small cell lung cancer whose cancer has progressed after a third-generation targeted therapy. About 430 adults will receive either the new drug or standard care. The goal is to see if …

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …

This Phase 3 trial tests whether adding an oral targeted therapy (calderasib) to an immunotherapy injection (pembrolizumab) helps people with a specific KRAS-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous NSCLC will…

This phase 2 trial is testing a drug called zanidatamab in 200 adults with advanced HER2-positive solid tumors, including breast, stomach, lung, and other cancers that have worsened after at least one prior treatment. The drug is given by IV and aims to shrink or control tumor gr…

This study tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) in people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. The goal is to see if the combination can shrink tumors and control the disease. About 57…

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This phase 2 trial is testing two drugs, ABSK043 and glecirasib, together in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The study will enroll 86 participants to see if the combination is safe and can shrink tumors. It is c…

This phase 3 trial tests whether adding the targeted drug calderasib (MK-1084) to the immunotherapy durvalumab can help people with a certain KRAS-mutated lung cancer live longer without their cancer growing. The study enrolls about 310 adults whose cancer has not progressed afte…

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. About 60 adults with operable stage IB-IIIA NSCLC will receive …

This early-phase trial is testing whether a combination of a healthy gut bacteria (EXL01) and the immunotherapy drug nivolumab can help people with advanced non-small cell lung cancer that no longer responds to standard treatments. The study will enroll 21 adults whose cancer has…

This study tests two experimental drugs, BNT326 and BNT327, in people with advanced non-small cell lung cancer that has spread or come back. The trial has three parts to find the best dose and check safety and effectiveness. About 420 adults will take part, and the drugs are give…

This phase 2 trial tests whether giving low-dose radiation along with two immunotherapy drugs (ipilimumab and nivolumab) before surgery can shrink tumors in people with stage IB to III non-small cell lung cancer. About 25 participants will receive the combination, then undergo su…

This Phase 3 trial tests whether adding the targeted drug calderasib to standard immunotherapy (pembrolizumab) can prevent lung cancer from returning in people with a specific KRAS mutation (G12C) after surgery. About 400 participants will receive either the combination or a plac…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and attack cancer cells that have a protein called PD-L1 on their surface. The study will involve about 30 adults with advanced solid tumors (like lung, breast, …

This Phase 2 trial tests whether adding the antidepressant olanzapine to standard immunotherapy (nivolumab) helps people with advanced EGFR-negative non-small cell lung cancer live longer. About 156 participants will receive either the combination or immunotherapy alone for 6-8 w…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced or metastatic solid tumors, including non-small cell lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults aged 18 to 75 who hav…

This early-stage study tests a new drug that delivers radiation directly to cancer cells in people with advanced pancreatic, lung, breast, or colorectal cancers. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 162 adults whose ca…

This study uses a blood test to detect tiny amounts of cancer DNA left after standard treatment for early-stage non-small cell lung cancer. People whose blood shows this leftover cancer are at higher risk of the cancer coming back. The study tests whether the drug durvalumab can …

This study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that targets cancer cells, followed by chemotherapy and an immunotherapy drug, and compares it to standard chemotherapy a…

This study tests whether adding a second immunotherapy drug (domvanalimab) to the standard drug durvalumab can better control stage III lung cancer that hasn't grown after initial chemo-radiation. About 860 adults with a specific type of lung cancer will receive either the combo …

This study tests whether adding low-dose radiation to the liver can help immunotherapy work better for people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive standard immunotherapy plus liver radiation. The goal is to s…

This study tests whether adding a third drug to standard immunotherapy (cemiplimab) plus chemotherapy works better for people with early-stage non-small cell lung cancer who can have surgery. About 120 adults will receive treatment before and after their operation. The main goal …

This study tests whether adding targeted, high-dose radiation to standard drug therapy (chemotherapy or immunotherapy) helps people with non-small cell lung cancer that has spread to up to 5 spots live longer. About 240 participants will be randomly assigned to receive either sta…

This study looks at whether adding a precise form of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastases w…

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 420 adults who have not had prior treatment for advanced dis…

This study tests a new oral drug called HEC169096 in people with advanced solid tumors, including thyroid cancer, non-small cell lung cancer, and others. The drug targets cancers with a specific genetic change (RET fusion or mutation). The trial has two phases: first to find the …

This study tests a new combination of drugs (SKB264 plus KL-A167, with or without chemotherapy) in about 110 adults with advanced or metastatic non-small cell lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow cancer growth. Participants must h…

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and …

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This study tests a new drug called HLX17, which is similar to the cancer drug Keytruda. It is for people who have had surgery for non-small cell lung cancer, melanoma, or kidney cancer. The goal is to see how the drug moves through the body, how safe it is, and how well it works …

This study compares a new drug, YL202, with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific EGFR mutation. Participants must have already tried an EGFR-targeted therapy and platinum chemo without success. The goal is to s…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This study tests an experimental oral drug, VMD-928, given alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. Ab…

This study tests a daily pill called sunvozertinib in 34 people with advanced non-small cell lung cancer that has certain uncommon EGFR gene changes. Participants have not had prior cancer treatment. The goal is to see if the drug can shrink tumors and delay cancer growth. This i…

This early-phase study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in a lab to better recognize and attack cancer cells. The main goal is to fi…

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This study tests a combination of furmonertinib (a targeted pill), chemotherapy injected into the spine, and precise radiation for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain and its lining. The goal is to see if this approach can contr…

This study is for people with a specific type of advanced lung cancer (ALK-positive) that has gotten worse during or after treatment with the drug lorlatinib. Researchers want to see if a different drug, iruplinalkib, can help control the cancer for a longer time. About 20 adults…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This study tests a new drug, ANS02, in about 294 adults with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check safety and find the right dose. Researchers will also see if the drug can shrink tumors. Participants must be in fairly …

This study tests whether a new drug, sacituzumab tirumotecan, given alone or with another drug (osimertinib), can shrink tumors before surgery in people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). About 60 adults aged 18-75 who have not had prio…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This study tests a treatment plan for people with stage IIIA or IIIB non-small cell lung cancer. Participants first receive three cycles of chemotherapy plus the immunotherapy drug atezolizumab. After that, a team decides if surgery is possible. Those who have surgery get more at…

This study tests whether adding a new drug (BL-B01D1) to the standard pill osimertinib works better than osimertinib alone for people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 720 adults will take part. The main goal is to see if the combin…

This study is for people with a certain type of lung cancer (stage IIB-IIIB) that can be removed with surgery. Participants first get chemotherapy plus the immunotherapy drug durvalumab before surgery. After surgery, those whose cancer did not fully disappear are randomly assigne…

This study tests whether adding the immunotherapy drug envafolimab to standard chemotherapy helps shrink tumors before surgery and delays cancer return in people with stage III non-small cell lung cancer. About 390 participants will receive either envafolimab plus chemo or a plac…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a new drug (QL1706) combined with chemotherapy given before surgery for people with a certain type of lung cancer (non-small cell lung cancer, stages IIB to IIIB). About 30 participants will receive the treatment for three cycles, then have surgery if possible. T…

This study tests a combination of two drugs—tulmimetostat (an EZH2 inhibitor) and pembrolizumab (an immunotherapy)—in 66 veterans with advanced non-small cell lung cancer that has worsened after initial treatment. The goal is to see if the combination can shrink tumors or slow ca…

This study tests whether higher doses of the targeted drug furmonertinib, alone or with chemotherapy, can help people with advanced EGFR-mutant non-small cell lung cancer whose cancer worsened after first-line treatment with a similar drug. About 60 participants will be randomly …

This study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…

This study tests whether using special MRI scans to guide radiation therapy can reduce lung damage and improve outcomes for people with advanced non-small cell lung cancer. About 490 adults with stage III lung cancer will receive radiation, chemotherapy, and immunotherapy. Half w…

This study tests a new treatment using specially engineered natural killer (NK) cells to attack advanced lung cancer that has spread. About 60 adults whose tumors have certain markers will receive chemotherapy followed by an infusion of these cells. The goal is to find a safe dos…

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…

This program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…

This early-phase study tests a new drug, ASP1002, in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants receive the drug throug…

This study looks at whether early heart monitoring and treatment can help people with advanced lung cancer who are receiving strong cancer therapies. About 524 adults with stage III non-small cell lung cancer will be enrolled. The goal is to see if this approach improves survival…

This study tests whether combining ivonescimab with either Dato-DXd or osimertinib is safe and works for people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatments. About 66 participants will receive different doses to find the …

This study tests a new drug, SAR445877, in people with advanced non-small cell lung cancer that has stopped responding to immunotherapy. The goal is to see if the drug can help control the cancer. About 29 adults will take part, and researchers will monitor safety and side effect…

This study tests whether a lower dose of chemotherapy combined with an immunotherapy drug can be a safer and still effective first treatment for older adults (70+) or those who are frail with advanced non-small cell lung cancer. The main goal is to see if fewer people have to sto…

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This study tests a new drug, taletrectinib, against the current standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 194 participants will be randomly assigned to take either taletrec…

This study tests an experimental pill called sutetinib in people with advanced lung cancer that has certain uncommon gene changes (EGFR mutations). The goal is to see if the drug can shrink tumors and control the disease. About 99 adults who have had no more than one prior chemot…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to recognize and attack unique mutations in their tumor, then infuse the…

This study tests a new drug, BMS-986517, in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goal is to check the drug's safety and find the right dose. About 315 participants with certain cancer types (like lung, head and neck, or brea…

This study tests whether adding the drug MK-2870 to standard pembrolizumab treatment helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will receive initial chemo plus pembrolizumab, then either continue pembrolizumab alone or add M…

This study tests the safety and effectiveness of combining two drugs, lorlatinib and ramucirumab, for people with advanced ALK-rearranged non-small cell lung cancer. About 56 adults will participate, starting with finding a dose that causes few side effects, then checking if the …

This study is for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. It compares two treatments: one using a single immunotherapy drug with chemotherapy, and another using two different immunotherapy drugs with chemotherapy. The goal is to see i…

This study looks at the best way to sequence EGFR-inhibitor drugs for people with advanced EGFR-mutated lung cancer that cannot be cured. About 200 participants will receive different orders of these targeted therapies, and researchers will track tumor response, side effects, and…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study tests a drug called pyrotinib as a first treatment for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. About 18 adults will take the pill daily to see if it shrinks tumors and how safe it is. The goal is to control the cance…

This study tests whether giving radiation to the main lung tumor before starting targeted therapy pills can delay cancer growth in people with advanced, gene-mutated non-small cell lung cancer. About 34 adults who have not yet had treatment will receive radiation to the primary l…

This study is for people with advanced non-small cell lung cancer whose previous treatment (PD-1/L1 therapy) stopped working. Researchers are testing a new combination of two drugs, ZG005 and gecacitinib, to see if it is safe and can shrink tumors. About 50 adults aged 18 to 75 w…

This study looks at whether adding surgery or radiation to the main tumor can help people with advanced EGFR-mutant lung cancer who have already responded to a combination of osimertinib and chemotherapy. About 70 adults will receive local therapy and be followed to see how long …

This early-stage trial tests a new drug called MST-0312 in people with advanced solid tumors like lung, melanoma, bladder, colorectal, and triple-negative breast cancer. The drug is designed to activate a natural immune pathway to help the body fight cancer more effectively. It i…

This study tests whether a new experimental drug (PF-08634404) combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to …

This study tests whether lower doses of chemotherapy can effectively control lung cancer in patients aged 70+ or those with other health problems. About 280 participants will receive pre-set reduced chemo doses to see if tumors shrink while causing fewer side effects. The goal is…

This study tests whether combining a targeted pill (adagrasib) with precise radiation (SRS) can control brain tumors in people with a specific type of advanced lung cancer (KRAS G12C mutation). About 30 adults with untreated brain metastases will receive both treatments. The main…

This study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who did well on initial immunotherapy but still have signs of cancer DNA in their blood. About 70 adults aged 18-75 will be randomly assigned…

This study tests whether giving the drug trastuzumab deruxtecan before routine surgery can shrink tumors in people with a specific type of lung cancer (HER2-amplified or HER2-mutated non-small cell lung cancer). About 14 adults with stage II to IIIB lung cancer will receive the d…

This early-phase study tests an experimental drug called PRTH-101, alone or with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors (like lung cancer) that haven't responded to standard treatments. The main goals are to check the drug's safety, fi…

This early-stage study is testing a new drug called BBO-8520 for people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check the drug's safety and see if it can shrink tumors. About 350 adults will take part, and the…

This early-phase study tests a new drug called PT0511 in adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works alone or w…

This study tests a new drug, ASP5834, in people with advanced solid tumors that have specific changes in the KRAS gene. The goal is to find a safe dose and check for side effects. Some participants with colorectal cancer will also receive another drug, panitumumab. The study is f…

This study tests two drugs, envafolimab and lenvatinib, together in people with advanced solid tumors (lung, kidney, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the combination can shrink tumors better than current options. About 17…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This early-stage trial tests a treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to attack the cancer…

This study tests an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has a marker called c-Met). Participants are randomly assigned to one of three different dose schedules of the d…

This study tests a new treatment for people with certain advanced cancers (like pancreatic, stomach, or colon cancer) that have a specific genetic change called KRAS G12V. The treatment involves taking a patient's own white blood cells, modifying them in a lab to better recognize…

This study tests whether using a protein-based test to guide treatment choices can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 56 adults with stage IIIC or IV lung cancer will be randomly assigned to either standard t…

This study tests a new drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers. The goal is to see if YL202 can shrink tumors and control the disease. Participants must be 18 or older and have a BMI between 18 and 32.

This program provides early access to the experimental drug zipalertinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after standard chemotherapy. It is for those who have no other good treatment …

This study tests whether giving high-precision radiation (SBRT) to all visible cancer spots can delay the disease from getting worse in people with 1 to 5 metastases from breast or lung cancer. About 145 participants will either receive standard care alone or standard care plus S…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors. The drug targets a protein found on cells that help tumors grow. The trial has two parts: first finding a safe dose, then testing if it works alone or with chemother…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This study compares a new drug called ivonescimab to the standard treatment pembrolizumab for people with advanced non-small cell lung cancer that has spread and shows high PD-L1 levels. About 780 adults with stage IV cancer will receive either drug as their first therapy. The go…

This study tests a new drug called LBL-024 combined with other medicines in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. About 230 adults aged 18-75 will take p…

This study tests an experimental drug called STX-721 in people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal is to find a safe dose and see if the drug can shrink tumors. About 345 participants will take the drug by mouth, …

This study tests a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. The study compares Ivonescimab to standard treatments and looks at how well it works and w…

This study tests whether combining two drugs, tepotinib and ivonescimab, is safe and works for people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. About 16 participants will try different doses to find the one with the fewes…

This study tests a new drug called YL202 combined with other anti-cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 414 adults aged 18-75 who have already tried stan…

This early-phase study tests whether adding a short course of high-dose radiation before standard chemotherapy and immunotherapy can help shrink borderline resectable non-small cell lung cancer before surgery. About 18 adults with stage II to IIIC lung cancer will receive three d…

This early-stage study tests a new drug (tolododekin alfa) combined with an existing immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors or slow disease progression. About 60 participants will join, including …

This study tests a combination of two drugs (HLX43 and serplulimab) given before surgery to people with non-small cell lung cancer. The goal is to see if this treatment can shrink tumors and improve outcomes. About 60 adults with stage II-IIIB lung cancer will participate.

This study tests whether adding a traditional Chinese herbal decoction (HGXJT) to standard immunotherapy can help control lung cancer that has spread to the bones. About 82 adults with a specific type of lung cancer (non-small cell, without certain gene mutations) will receive ei…

This study tests whether adding radiotherapy to immunotherapy after surgery can help people with a certain type of advanced lung cancer (stage III N2 non-small cell lung cancer) live longer without the cancer coming back. About 60 adults aged 18 to 75 who have had surgery and hav…

This study tests a new drug called TUB-040 in people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is designed to deliver a cancer-killing agent directly to tumor cells that have a specific marker (…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This study is for people with advanced non-small cell lung cancer who are not well enough for standard strong chemotherapy. It tests a combination of one chemotherapy drug and an immunotherapy drug (pembrolizumab) to see if it is safe and helps shrink tumors. About 60 participant…

This study tests an experimental drug called TNG260 combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific gene change (STK11 mutation). The goal is to find the best dose and see if the combination is safe and can shrink tumors. A…

This study tests whether combining an immunotherapy drug (toripalimab) with a cold-based tumor destruction technique (cryoablation) can help control advanced non-small cell lung cancer that has started to grow again after initial treatment. About 54 adults with limited new tumor …

This study is for veterans with stage 3 non-small cell lung cancer that cannot be removed by surgery. It combines chemotherapy, immunotherapy, and radiation to see if this approach helps control the cancer longer and is safe. About 25 participants will receive the treatment, and …

This study tests whether removing extra safety margins during MRI-guided radiation can safely treat lung cancer that has spread to the brain. About 168 adults with 1 to 10 brain metastases will receive precise, adaptive radiation without the usual buffer zone. The goal is to redu…

This study tests a new drug called SHR-A2102 combined with other cancer treatments for people with a type of lung cancer that can be removed by surgery. The goal is to see if the combination can destroy more cancer cells before and after the operation, helping patients live longe…

This early-phase study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in about 590 adults with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated with immunotherapy and platinum chemo. The goal is to see if the new dr…

This study is for people with a type of lung cancer that has spread to only a few places in the body and has a specific gene change. Participants will either continue taking their targeted therapy pills alone or also receive radiation to the cancer spots. The goal is to see if ad…

This study compares two types of minimally invasive lung surgery for people with early-stage non-small cell lung cancer: robot-assisted surgery (RATS) and video-assisted surgery (VATS). About 1,124 participants will be randomly assigned to one of the two procedures. The main goal…

This early-phase study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to other treatments. The main goals are to check safety and find the best dose. A…

This early-stage trial tests whether adding Tumor Treating Fields (TTFields) to standard chemoradiation and immunotherapy is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. About 30 participants will receive TTFields alongside their us…

This study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…

This study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 278 adults will take part across 10 countries. The study is open to those with a speci…

This study tests a new oral drug, sutetinib maleate, in people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal is to see if the drug can shrink tumors or slow cancer growth. About 66 adults will take the capsule and be monitored for response an…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This study tests a new drug, WSD0922-FU, in 40 adults with advanced non-small cell lung cancer that has a specific genetic change (C797S mutation) and has stopped responding to the standard first treatment, osimertinib. The goal is to see if the drug can shrink tumors or slow the…

This study tests whether adding the experimental drug SHR-A2009 to the standard pill aumolertinib works better than aumolertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 576 adults who have not had prior treatment will be randomly…

This study tests a new treatment using a patient's own immune cells (called TILs) to prevent non-small cell lung cancer from returning after surgery. About 45 adults who have already had chemotherapy and surgery will be randomly assigned to receive either TILs plus standard care,…

This study tests whether a lower dose of the targeted therapy osimertinib can control advanced EGFR-positive non-small cell lung cancer while reducing side effects. About 58 adults with this specific genetic type of lung cancer will receive 80 mg every other day. Researchers will…

This study compares two treatments for people with advanced squamous non-small cell lung cancer who have not had prior therapy. Participants will receive either the experimental drug RC148 or the approved drug tislelizumab, both combined with chemotherapy. The goal is to see whic…

This study tests a new approach for people with stage II to III non-small cell lung cancer that can be surgically removed. Before surgery, patients receive low-dose radiation plus focused high-dose radiation, followed by a combination of an immunotherapy drug (tislelizumab) and s…

This study tests two experimental drugs, SI-B003 and BL-B01D1, alone or together, in people with advanced lung cancer or nasopharyngeal cancer that has spread. About 121 adults aged 18 to 75 will take part to see if the combination shrinks tumors and to find the best dose. The go…

This study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…

This study tests whether adding AGuIX nanoparticles to precise, MRI-guided radiation can better control centrally located lung tumors and advanced pancreatic cancer. About 100 adults with these cancers will receive the combination therapy. The goal is to find the safest dose and …

This early-phase study tests a vaccine that targets specific KRAS mutations in advanced non-small cell lung cancer. About 12 participants will receive the vaccine alongside standard chemotherapy and two immunotherapy drugs (nivolumab and ipilimumab). The main goal is to check saf…

This study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study tests whether adding a special type of radiation (SFRT) to standard cancer treatment can help control non-small cell lung cancer that has started to grow again after initial therapy. About 25 adults whose cancer has progressed in a limited number of spots will receive …

This study looks at whether giving radiation to the chest after surgery and chemo-immunotherapy can help people with stage III non-small cell lung cancer who still have signs of cancer after treatment. About 118 adults will be randomly assigned to receive or not receive radiation…

This study tests several new drug combinations given before and after surgery for people with early-stage non-small cell lung cancer. The goal is to see if these combinations can destroy more cancer cells and prevent the cancer from coming back. About 630 adults with stage II to …

This study tests whether a new drug (divarasib) combined with immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not had…

This study tests a treatment that uses immune cells taken from a patient's own lung tumor. These cells are grown in large numbers and given back to the patient to attack the cancer. The trial includes 30 adults with advanced non-small cell lung cancer that has worsened after stan…

This study tests a drug called DRP-104 in people with advanced non-small cell lung cancer that has specific gene changes (NFE2L2 or KEAP1). The drug works by blocking glutamine, a nutrient cancer cells need to grow. The trial aims to see if the drug can shrink tumors or slow the …

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after lung cancer surgery. People whose blood shows these cancer signals will get extra treatment (chemotherapy and immunotherapy) to try to stop the cancer from coming back. The goa…

This study tests an experimental pill called WJ22096 in about 20 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants take the pill by m…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study tests a daily pill called sunvozertinib against a placebo in 360 people with a specific type of lung cancer (stage IB-IIIA) who have had surgery to remove their tumor. The goal is to see if the drug can stop the cancer from returning. Participants must have certain EGF…

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This early-stage study tests a new drug called AOH1996 in adults with solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and check for side effects. About 92 people with cancers like lung, ovarian, or pancreatic cancer will …

This study tests whether giving a precise, high-dose radiation treatment (SBRT) before chemotherapy can better control stage III non-small cell lung cancer. It involves 20 adults aged 18-75 with tumors smaller than 6 cm. The goal is to see if this combination improves local tumor…

This study tests a new drug called sunvozertinib combined with chemotherapy in people with advanced non-small cell lung cancer that has specific EGFR mutations. Participants must have already tried and failed an EGFR-targeted therapy. The goal is to see if the combination can shr…

This study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better t…

This study is for people with a type of advanced lung cancer (non-small cell) that cannot be treated with surgery or standard chemo-radiation. It tests adding experimental drugs that block DNA repair to standard radiation therapy, followed by a year of immunotherapy (durvalumab).…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or prostate cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants…

This study tests two experimental drugs, DZD9008 and AZD4205, together in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard treatments. About 90 adults will take part to see if the combination is…

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that worsened after prior immunotherapy. About 630 adults will receive either the new drug or chemotherapy every 3 weeks for up to…

This study tests a new surgical technique called septum-guided segmentectomy for people with small, early-stage lung cancer located deep in the lung. The goal is to remove the cancer completely while saving as much healthy lung tissue as possible, which may help preserve breathin…

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This study tests a new pill called dositinib for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). The goal is to find a safe dose and see if it shrinks tumors. About 153 adults aged 18-75 who have tried other treatments without succ…

This study tests whether the drug ivonescimab, given after standard radiation therapy (SBRT), can help prevent early-stage non-small cell lung cancer from returning. About 36 people with tumors up to 7 cm will receive the drug as a consolidation treatment. The main goal is to see…

This study tests whether adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer that has low PDL1 levels. The trial has two parts: first finding the best dose, t…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This study tests whether adding new drugs, like patritumab deruxtecan, to standard immunotherapy (pembrolizumab) with or without chemotherapy can better treat advanced non-small cell lung cancer that has spread. About 90 people with untreated stage IV NSCLC will participate. The …

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…

This study tests the drug cabozantinib in people with advanced non-small cell lung cancer whose tumors have certain gene changes (RET, ROS1, NTRK fusions or increased MET/AXL activity). The drug is taken by mouth and aims to shrink tumors and stop them from growing. About 86 part…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment …

This study tests whether adding the experimental drug MK-1084 to standard immunotherapy (pembrolizumab) helps people with a specific genetic form of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 600 adults with newly diagnosed, advanced…

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer still shows signs of activity (detected by a blood test) after taking the drug osimertinib alone. The trial will test whether adding a second drug, sacituzumab tirumotecan, can improve out…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study tests whether a focused ultrasound device can safely open the blood-brain barrier in people with non-small cell lung cancer that has spread to the brain. About 30 participants will receive standard immunotherapy plus the ultrasound procedure. The goal is to see if this…

This study tests whether adding targeted radiotherapy to usual drug therapy can slow the growth or spread of metastatic non-small-cell lung cancer. About 320 adults whose cancer has started to grow in a few spots while on first-line treatment will receive either standard drugs al…

This study tests a new drug called FMC-376 in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and shrinks tumors. About 403 adults with lung, colorectal, or pancreatic cancer that has spread or cannot …

This early-phase study tests a new drug called GNC-077, a multi-specific antibody injection, in about 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs…

This study tests whether adding the experimental drug SKB264 to the immunotherapy pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks the PD-L1 protein. About 432 adults with stage IIIB/IV disease w…

This early study is testing a new imaging agent called FL-261 in 12 people with advanced cancers like lung, colorectal, or head & neck cancer. The agent targets a protein called c-MET that is often found on cancer cells. Researchers want to see if FL-261 scans can safely and accu…

This study is testing whether a special type of PET scan (FAPI-PET/CT) and a fluorescent dye can help doctors see how well lung cancer has responded to pre-surgery treatment and find the exact tumor location during surgery. About 200 people with stage II-IIIB lung cancer will get…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study tests two new radioactive imaging agents (JFI447 and FFG233) to see how well they show up on PET scans in people with advanced solid tumors like pancreatic, lung, breast, colorectal cancers, and sarcomas. The goal is to measure how the agents spread in the body and com…

This study tests a new imaging agent (68GaNOTA-anti-MMR-VHH2) that attaches to certain immune cells (macrophages) in lung tumors. About 20 adults with non-small cell lung cancer scheduled for surgery will receive a PET scan with this tracer before their operation. The goal is to …

This early-phase study is testing a special PET imaging agent called [89Zr]Zr-DFO-emapalumab to see if it can detect non-small cell lung cancer lesions and show how well the cancer responds to immunotherapy. Six adults with newly diagnosed lung cancer will receive the imaging age…

This early-phase study is testing a new radioactive tracer for PET scans that may better detect non-small cell lung cancer that has spread to the brain. About 20 adults with this type of lung cancer and brain metastases will receive the tracer and undergo imaging. The goal is to …

This study is testing a new radioactive tracer called 68Ga-TOI-1 for PET scans in people with lung cancer or suspicious lung nodules. The goal is to see if it can find and stage tumors more accurately than the standard FDG-PET scan. About 80 adults will receive the tracer and und…

This study is testing a blood test that looks for tumor DNA to see if it can more accurately tell whether a lung nodule found on a CT scan is cancer. About 590 people getting lung cancer screening will give blood samples and be followed for 3 years. The goal is to improve how we …

This study tests a special PET probe called [68Ga]CBP8 to see if it can detect tissue damage caused by radiation therapy in people with lung or pancreatic cancer. About 72 participants will get a PET scan before and 3-6 months after radiation. The goal is to find early signs of r…

This study is testing whether an artificial intelligence (AI) system can accurately identify different types of lung cancer by analyzing PET/CT scans and patient information like age, smoking history, and tumor markers. Researchers aim to improve how doctors distinguish between s…

This early-stage study tests a new imaging drug called [18F]DK222 in 6 people with lung or bladder cancer. The drug is designed to attach to a protein (PD-L1) that cancers use to hide from the immune system. The main goal is to check the drug's safety and how it moves through the…

This study tests whether a special microscope (CLE) can help doctors identify non-small cell lung cancer in real time during a biopsy. About 70 adults with suspected lung tumors will have standard biopsy plus CLE imaging. Researchers will compare the CLE score to standard lab res…

This study tests whether 10 weeks of online singing training can help people who still have symptoms like breathlessness 6 to 18 months after surgery for non-small cell lung cancer. Researchers will compare singing sessions to usual care in 100 participants, measuring changes in …

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This study tests whether adding pentoxifylline and vitamin E to standard chemoradiation can prevent lung injury (pneumonitis) in 150 adults with stage III non-small cell lung cancer. The goal is to reduce side effects and improve quality of life without affecting cancer treatment…

This study compares two ways of doing breathing exercises before and after lung cancer surgery: in-person sessions with a physiotherapist versus using a smartphone app (Fissios App) alongside those sessions. The goal is to see if the app helps reduce complications like infections…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This phase 3 trial tests whether a daily nutritional drink (Oral Impact®) can reduce severe throat and esophagus inflammation caused by chest radiation in lung cancer patients. About 121 adults with lung cancer who need radiation will drink two bottles a day during and for three …

This study tests whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to standard immunotherapy can help people with advanced non-small cell lung cancer who are too weak for aggressive treatment. About 120 participants will receive either real or sh…

This study tests a 12-week home-based coaching program for people who had surgery for early-stage lung cancer. Participants wear a Fitbit and get personalized step goals and coach calls to help them move more. The goal is to see if this support improves daily physical activity co…

This study tests whether using a smaller chest drain (16F) causes less pain after minimally invasive lung surgery compared to the standard larger drain (24F). About 124 adults having lung lobe or segment removal will be randomly assigned to one drain size. Pain levels while cough…

This study tests a new drug called JMT203 in people with lung or pancreatic cancer who are experiencing severe weight loss (cachexia). The goal is to see if the drug is safe and can help patients gain or maintain weight. About 307 adults will take part in this early-phase trial a…

This study tests whether a wearable smart patch can help catch serious side effects early in cancer patients receiving chemotherapy or immunotherapy. About 30 adults with certain cancers will wear the Alio Smartpatch, which continuously tracks vital signs and blood levels. The go…

This study tests a mobile app that guides lung cancer patients and their family caregivers through yoga exercises at home. The goal is to see if the app is safe, easy to use, and helpful during radiation treatment. About 60 patient-caregiver pairs will participate.

This study tests whether a mix of home and center exercise sessions works as well as all-center sessions for people with non-small cell lung cancer before surgery. About 38 adults will take part, doing 15 exercise sessions over three weeks. The goal is to see if the hybrid approa…

This study follows 180 people with early-stage lung cancer to see if a smaller surgery (segmentectomy) leads to less shortness of breath and better quality of life compared to a larger surgery (lobectomy). Participants answer questionnaires before surgery and at several points du…

This study tests whether a new version of megestrol acetate can help people with advanced lung cancer maintain their appetite and body weight while undergoing chemotherapy and radiation. About 134 participants will receive either the study drug or a placebo alongside standard can…

This study looks at whether a simple exercise program is practical and helpful for people with non-small cell lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs (patient and caregiver) will take part. The goal is to see if exercising…

This study tests whether a supervised exercise program is safe and doable for people with lung cancer who are receiving radiation and chemotherapy. Ten participants will do breathing exercises, walking or cycling, and light strength training during their treatment. The goal is to…

This study looks at whether pulmonary rehabilitation—a program of exercise and breathing techniques—can improve breathing, fatigue, and quality of life for people with advanced non-small cell lung cancer. Half of the 85 participants will do an 8-week rehab program, while the othe…

This study tests a new way to remove small lung tumors using a 3D computer model and a dye that makes the tumor glow during surgery. The goal is to help surgeons remove only the diseased part of the lung, avoiding a full lobe removal. About 32 adults with early-stage lung cancer …

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers grow and why some respond differently to treatments. Participants may undergo apheresis, biopsies,…

This observational study is following 100 adults with metastatic non-small cell lung cancer who have certain EGFR mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers want to see how long the treatment keeps the can…

This pilot study is collecting stool and saliva samples from 82 people with advanced non-small cell lung cancer to see if the diversity of their gut microbiome is linked to how well their treatment works and what side effects they experience. The goal is to better understand the …

This study follows 500 European patients with advanced non-small cell lung cancer who are already prescribed cemiplimab (Libtayo) as part of their normal care. Researchers will track how long patients live, how well the cancer responds, and any side effects. The goal is to see if…

This study aims to collect and analyze tumor tissue from 550 adults with advanced non-small-cell lung cancer in Taiwan. Researchers will use genetic sequencing to find mutations that may explain why some treatments stop working and to identify new treatment options. The goal is t…

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, gastric, or liver) who are starting immunotherapy. Researchers want to see if changes in ctDNA (bits of tumor DNA in the blood) can predict early whether the treatment is working. They will also ch…

This observational study aims to understand why some ROS1-positive non-small cell lung cancers stop responding to the drug entrectinib. Researchers will analyze tissue or blood samples from 38 patients who have already taken entrectinib as part of their regular care. By using gen…

This study is collecting blood and tumor samples from 200 people with non-small cell lung cancer to find biological markers that predict whether immunotherapy will work. Researchers will compare samples taken before treatment and at the time the disease gets worse. The goal is to…

This study is collecting blood and tumor samples from 1,100 people with head and neck, ovarian, cervical, lung, brain, or anal cancer. Researchers want to learn how immune cells called T cells behave in different tumors. The goal is to better understand why some cancers respond t…

This study is not testing a new drug but rather collecting information from 130 people with advanced lung cancer who have a specific gene mutation (EGFR). All participants will receive the standard drug osimertinib as their first treatment. Researchers will track how long the can…

This study is watching how patients with EGFR-mutated non-small cell lung cancer do when they receive standard treatment with osimertinib (Tagrisso) alone or with chemotherapy in routine medical practice. About 538 people with advanced lung cancer will be followed to see how long…

This study looks at how the body's metabolism may influence whether immunotherapy works for people with non-small cell lung cancer. Researchers will collect and analyze tissue samples from 150 patients to compare those who respond to treatment with those who don't. The goal is to…

This study uses lab-grown tumor samples from 5 lung cancer patients to test whether natural compounds (resveratrol and artichoke extract) can make immunotherapy work better and cause fewer side effects. The goal is to find better drug combinations, not to cure the disease directl…

This study is not testing a new treatment. Instead, it collects information from 650 people with advanced lung cancer to create 'control groups' that can be used in future research. Participants continue their standard care while researchers track how well their treatments work. …

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study aims to see how well different laboratory tests agree when looking for a specific gene change (MET) in lung cancer tumors. About 1000 people with untreated non-small cell lung cancer will provide tumor samples for testing. The results will help doctors choose the most …

This study looks at how adults aged 70 and older with non-small cell lung cancer are treated in everyday medical practice. Researchers will track 500 participants to understand which treatments work best, how safe they are, and how they affect quality of life. The goal is to gath…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic markers. The goal is …

This study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…

This study uses surveys to find out what factors are most important to Chinese patients and doctors when choosing the first targeted therapy for advanced lung cancer. About 590 participants (patients and physicians) will answer questions about treatment preferences. The goal is t…

This study looks at why amivantamab, a drug for advanced non-small cell lung cancer with a specific EGFR mutation, stops working over time. Researchers will collect blood and tumor samples from 30 patients when their disease gets worse. The goal is to find genetic changes that ca…

This study looks at whether eating more fermented foods or taking extra fiber can change the bacteria in your gut and help your immune system fight cancer better. It involves 70 adults with melanoma or lung cancer who are already receiving standard immunotherapy. Participants wil…

This study is testing a new technology called an electronic nose (E-nose) that analyzes chemicals in a person's breath. Researchers want to see if it can measure how well lung cancer responds to treatment and detect if the cancer comes back. About 60 people with non-small cell lu…

This study looks at why some lung cancer cells survive targeted treatment. Researchers will take small tissue samples (biopsies) from 100 patients before and two weeks after starting therapy. By comparing the samples, they hope to find early signs of resistance and identify ways …

This study involves 50 adults with lung cancer whose disease has worsened while on immunotherapy. Researchers will take a new tumor sample (rebiopsy) to study why the treatment stopped working. The goal is to better understand resistance mechanisms, not to provide a direct treatm…

This study tests whether an artificial intelligence (AI) model can help doctors make better treatment decisions for non-small cell lung cancer (NSCLC). About 300 patients will have their treatment plans created by both a standard team of doctors and the AI. Researchers will compa…

This study looks at 60 adults with early-stage non-small cell lung cancer whose cancer came back after surgery and treatment with the drug osimertinib. Researchers will analyze tumor or blood samples to find genetic changes linked to the recurrence. The goal is to better understa…

This study looks at whether regularly measuring the amount of pembrolizumab (an immunotherapy drug) in the blood can help doctors better treat non-small cell lung cancer. The goal is to see if this monitoring can improve how well the drug works and reduce side effects. About 75 a…

This study tests whether a new technology called Markerless Tumour Tracking can accurately guide lung cancer radiotherapy without the need for implanted markers. About 30 people with early-stage lung cancer or limited lung metastases will participate. The goal is to see if the ne…

This study is for people aged 70 and older with early-stage lung cancer who are scheduled for surgery. Researchers want to see if markers of aging (like changes in DNA and cell health) can help predict who will have complications or need unplanned hospital stays. The goal is to u…

This study looks at whether a special PET scan can tell early on if immunotherapy (with or without chemo) is working for advanced lung cancer. It aims to tell the difference between true tumor growth and harmless inflammation that can look like growth. About 200 adults with non-s…

This study looks at how a 12-week exercise program affects the immune system of people with lung cancer. Researchers will compare two types of exercise (moderate vs. high intensity) to standard care. They will measure changes in immune cells and other markers in the blood to see …

This study looks at whether adding febuxostat (a gout medicine) to the standard lung cancer drug osimertinib can increase the amount of osimertinib that reaches the brain. It involves 7 adults with a specific type of advanced lung cancer who are already taking osimertinib. Resear…

This study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand which cancers might respond to a future CAR T-cell therapy and to store participants' own immune cells for potential …

This study looks at whether a lab-grown model of a patient's own lung cancer cells can help doctors choose the most effective drugs. Researchers will compare the model's predictions with how the patient actually responds to treatment. The goal is to see if this approach can guide…

This observational study will follow about 500 adults in Spain with EGFR-mutated non-small cell lung cancer who are taking the drug osimertinib. Researchers want to see how well the drug works in everyday medical practice, including survival rates, treatment adherence, and qualit…

This study collects blood samples and health information from 1,200 people with non-small cell lung cancer. Researchers want to learn how the cancer changes during standard treatment and whether simple blood tests can predict if the cancer will come back. Participants continue th…

This study looks at the biological features of a specific type of lung cancer (ALK-positive) in 100 patients. Researchers will analyze tumor samples and blood tests taken at diagnosis and when the disease worsens. The goal is to learn why some treatments stop working, not to test…

This study uses machine learning to analyze real-world data from over 144,000 people with advanced non-small cell lung cancer. The goal is to find which existing treatments work best for different patient groups, helping doctors make more personalized choices. Participants' healt…

This study aims to understand cancer-related fatigue in people with non-small cell lung cancer who are receiving immunotherapy. Researchers will interview 20 patients about their fatigue, daily function, and views on physical activity. The goal is to learn how fatigue affects pat…

This observational study looks at 300 people with early-stage lung cancer to understand why different types of the disease behave differently. Researchers will analyze genes, immune cells, and other markers from tumor samples. The goal is to find patterns that could lead to bette…

This study reviews medical records of 150 patients with inoperable lung cancer that returned after previous radiation. Researchers want to learn if giving another round of high-precision radiation (SBRT) is safe and effective. The goal is to help doctors make better treatment dec…

This study looks at whether adding a simple blood test that detects tumor DNA (ctDNA) to regular scans can help doctors choose better treatments for people with advanced colorectal or non-small cell lung cancer. About 332 adults with cancer that has spread will be randomly assign…

This study tests whether a natural supplement called urolithin A (MitoPure®) can improve the immune response in people with solid tumors like lung cancer or melanoma who are starting standard immunotherapy. About 45 participants will be randomly assigned to take either the supple…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study tests a new way to predict how well your lungs will work after lung cancer surgery. Doctors will use 3D CT scans to create a virtual model of your lungs and simulate the surgery beforehand. The goal is to see if this method is more accurate than current techniques, hel…

This study is observing 300 adults with kidney, bladder, lung, or liver cancer who are starting immunotherapy (PD-1/PDL-1 inhibitors). Researchers will measure a protein called Galectin-3 in the blood before each treatment to see if its level is linked to how well the therapy wor…

This study collects tumor tissue, blood, and other samples from 2,000 adults with certain lung and thymic cancers. Researchers will use these samples to learn more about how these cancers grow and change over time. The goal is to find new ways to diagnose and treat these diseases…

This study aims to learn more about lung cancer in adults diagnosed at age 45 or younger. Researchers will collect blood samples and medical information from 500 participants to study the biology of these cancers and look for genetic changes that could lead to better treatments. …

This study looks at blood, urine, and bone marrow samples from 620 people with solid cancers (like lung, colon, or pancreatic cancer) to find and measure tumor cells and DNA. The goal is to better understand how cancer spreads and returns after surgery. Participants include cance…